And GSK announced Thursday that the FDA had approved its medication gepotidacin, with the brand name Blujepa, as oral tablets ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

Gonorrhea is a common sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. It primarily infects the ...

New surveillance data from WHO warn of a concerning trend — drug-resistant gonorrhea, which has been a public health concern for years, is surging. Data reported by 12 countries to WHO’s Enhanced ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...

A single-dose oral medication called zoliflodacin shows promise as a new treatment for antibiotic-resistant gonorrhoea, ...

Marina Joubert receives funding from The British Academy as a member of the "Just Transitions for AMR" global convening.

Zoliflodacin is the first of a new class of antibiotics, called spiropyrimidinetriones, that have activity against Neisseria ...

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational ...

The FDA approved gepotidacin (Blujepa), an oral option for the treatment of uncomplicated urogenital gonorrhea among patients ...